The availability of 750 mcg parathyroid hormone administered dose in Australia remains constrained, primarily because of its niche therapeutic use in addressing severe osteoporosis. Market are mostly managed through specialist chemists and medical settings, necessitating a doctor's order and qualified clinical evaluation. While sourced versions can